| 出品公司: | |
|---|---|
| 载体名称: | pET-23a |
| 质粒类型: | 大肠杆菌表达载体；蛋白纯化 |
| 高拷贝/低拷贝: | 低拷贝 |
| 克隆方法: | 多克隆位点；限制性内切酶 |
| 启动子: | T7/ lacI |
| 载体大小: | 3592 bp |
| 5' 测序引物及序列: | T7 Fwd: 5'd[TAATACGACTCACTATAGGG]3' |
| 3' 测序引物及序列: | -- |
| 载体标签: | His Tag （C-端） |
| 载体抗性: | 氨苄青霉素（Ampicillin） |
| 克隆菌株: | DH5a |
| 表达菌株: | BL21系列 |
| 备注: | pET-23a，b，c仅阅读框（读码框）不同，彼此相差1个bp。 |
| 产品目录号: | ZY71553-3 |
| 稳定性: | 稳表达 |
| 组成型/诱导型: | 诱导型（IPTG) |
| 病毒/非病毒: | 非病毒 |
- ¥1100
- ZYbscience
- 中国/美国
- ZY71553-3
- 2025年07月12日
11 年钻石会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-20℃低温保存
- 保质期：
三年
- 英文名：
pET-23(+)
- 库存：
20
- 供应商：
泽叶生物
pET23载体基本信息
pET23载体质粒图谱和多克隆位点信息
| Feature Name | Start | End | |
|---|---|---|---|
| T7_terminator | 129 | 1 | |
| T7_Terminal_primer | 69 | 87 | |
| T7_promoter | 245 | 227 | |
| ROP | 754 | 945 | |
| pGEX_3_primer | 961 | 939 | |
| pBR322_origin | 1979 | 1360 | |
| Ampicillin | 2994 | 2134 | |
| AmpR_promoter | 3064 | 3036 |
| ORF | Start | End | |
|---|---|---|---|
| ORF frame 2 | 2994 | 2134 |
| Enzyme Name | Cut |
|---|---|
| XhoI | 158 |
| NotI | 166 |
| EagI | 166 |
| HindIII | 173 |
| SalI | 179 |
| SacI | 190 |
| EcoRI | 192 |
| BamHI | 198 |
| BglII | 260 |
| MscI | 285 |
| PvuII | 905 |
| PstI | 2452 |
pET23载体简介
pET-23(+) (Cat. No. 69771-3) is a transcription vector designed for expression from bacterial translation signals carried within a cloned insert. It therefore lacks the ribosome binding site and ATG start codon present on the pET translation vectors. A C-terminal His•Tag® sequence is available. Unique sites are shown on the circle map. Note that the sequence is numbered by the pBR322 convention, so the T7 expression region is reversed on the circular map. The cloning/expression region of the coding strand transcribed by T7 RNA polymerase is shown below. The f1 origin is oriented so that infection with helper phage will produce virions containing single-stranded DNA that corresponds to the coding strand. Therefore, single-stranded sequencing should be performed using the T7 terminator primer (Cat. No. 69337-3).
pET23载体序列
LOCUS pET-23(+) 3592 bp DNA SYN
DEFINITION pET-23(+)
ACCESSION
KEYWORDS
SOURCE
ORGANISM other sequences; artificial sequences; vectors.
COMMENT This file is created by Vector NTI
http://www.biofeng.com/
COMMENT ORIGDB|GenBank|
COMMENT VNTAUTHORNAME|biofeng.com|
COMMENT VNTOAUTHORAD1|Novagen Inc.|
FEATURES Location/Qualifiers
source 1..3592
/organism="pET-23(+)"
/mol_type="other DNA"
terminator complement(1..129)
/label="T7_terminator"
misc_feature 69..87
/label="T7_Terminal_primer"
promoter complement(227..245)
/label="T7_promoter"
misc_feature 754..945
/label="ROP"
misc_feature complement(939..961)
/label="pGEX_3_primer"
rep_origin complement(1360..1979)
/label="pBR322_origin"
gene complement(2134..2994)
/label="Ampicillin"
/gene="Ampicillin"
CDS complement(2134..2994)
/label="ORF frame 2"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
promoter complement(3036..3064)
/label="AmpR_promoter"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
ORIGIN
1 atccggatat agttcctcct ttcagcaaaa aacccctcaa gacccgttta gaggccccaa
61 ggggttatgc tagttattgc tcagcggtgg cagcagccaa ctcagcttcc tttcgggctt
121 tgttagcagc cggatctcag tggtggtggt ggtggtgctc gagtgcggcc gcaagcttgt
181 cgacggagct cgaattcgga tcctagaggg aaaccgttgt ggtctcccta tagtgagtcg
241 tattaatttc gcgggatcga gatctcgggc agcgttgggt cctggccacg ggtgcgcatg
301 atcgtgctcc tgtcgttgag gacccggcta ggctggcggg gttgccttac tggttagcag
361 aatgaatcac cgatacgcga gcgaacgtga agcgactgct gctgcaaaac gtctgcgacc
421 tgagcaacaa catgaatggt cttcggtttc cgtgtttcgt aaagtctgga aacgcggaag
481 tcagcgccct gcaccattat gttccggatc tgcatcgcag gatgctgctg gctaccctgt
541 ggaacaccta catctgtatt aacgaagcgc tggcattgac cctgagtgat ttttctctgg
601 tcccgccgca tccataccgc cagttgttta ccctcacaac gttccagtaa ccgggcatgt
661 tcatcatcag taacccgtat cgtgagcatc ctctctcgtt tcatcggtat cattaccccc
721 atgaacagaa atccccctta cacggaggca tcagtgacca aacaggaaaa aaccgccctt
781 aacatggccc gctttatcag aagccagaca ttaacgcttc tggagaaact caacgagctg
841 gacgcggatg aacaggcaga catctgtgaa tcgcttcacg accacgctga tgagctttac
901 cgcagctgcc tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg
961 gagacggtca cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg
1021 tcagcgggtg ttggcgggtg tcggggcgca gccatgaccc agtcacgtag cgatagcgga
1081 gtgtatactg gcttaactat gcggcatcag agcagattgt actgagagtg caccatatat
1141 gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac cgcatcaggc gctcttccgc
1201 ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg tatcagctca
1261 ctcaaaggcg gtaatacggt tatccacaga atcaggggat aacgcaggaa agaacatgtg
1321 agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca
1381 taggctccgc ccccctgacg agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa
1441 cccgacagga ctataaagat accaggcgtt tccccctgga agctccctcg tgcgctctcc
1501 tgttccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg gaagcgtggc
1561 gctttctcat agctcacgct gtaggtatct cagttcggtg taggtcgttc gctccaagct
1621 gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg
1681 tcttgagtcc aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag
1741 gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt ggcctaacta
1801 cggctacact agaaggacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg
1861 aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggtttttt
1921 tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct caagaagatc ctttgatctt
1981 ttctacgggg tctgacgctc agtggaacga aaactcacgt taagggattt tggtcatgag
2041 attatcaaaa aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat
2101 ctaaagtata tatgagtaaa cttggtctga cagttaccaa tgcttaatca gtgaggcacc
2161 tatctcagcg atctgtctat ttcgttcatc catagttgcc tgactccccg tcgtgtagat
2221 aactacgata cgggagggct taccatctgg ccccagtgct gcaatgatac cgcgagaccc
2281 acgctcaccg gctccagatt tatcagcaat aaaccagcca gccggaaggg ccgagcgcag
2341 aagtggtcct gcaactttat ccgcctccat ccagtctatt aattgttgcc gggaagctag
2401 agtaagtagt tcgccagtta atagtttgcg caacgttgtt gccattgctg caggcatcgt
2461 ggtgtcacgc tcgtcgtttg gtatggcttc attcagctcc ggttcccaac gatcaaggcg
2521 agttacatga tcccccatgt tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt
2581 tgtcagaagt aagttggccg cagtgttatc actcatggtt atggcagcac tgcataattc
2641 tcttactgtc atgccatccg taagatgctt ttctgtgact ggtgagtact caaccaagtc
2701 attctgagaa tagtgtatgc ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa
2761 taccgcgcca catagcagaa ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg
2821 aaaactctca aggatcttac cgctgttgag atccagttcg atgtaaccca ctcgtgcacc
2881 caactgatct tcagcatctt ttactttcac cagcgtttct gggtgagcaa aaacaggaag
2941 gcaaaatgcc gcaaaaaagg gaataagggc gacacggaaa tgttgaatac tcatactctt
3001 cctttttcaa tattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt
3061 tgaatgtatt tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc
3121 acctgaaatt gtaaacgtta atattttgtt aaaattcgcg ttaaattttt gttaaatcag
3181 ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac
3241 cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaacgtgga
3301 ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggcccactac gtgaaccatc
3361 accctaatca agttttttgg ggtcgaggtg ccgtaaagca ctaaatcgga accctaaagg
3421 gagcccccga tttagagctt gacggggaaa gccggcgaac gtggcgagaa aggaagggaa
3481 gaaagcgaaa ggagcgggcg ctagggcgct ggcaagtgta gcggtcacgc tgcgcgtaac
3541 caccacaccc gccgcgctta atgcgccgct acagggcgcg tcccattcgc ca
DEFINITION pET-23(+)
ACCESSION
KEYWORDS
SOURCE
ORGANISM other sequences; artificial sequences; vectors.
COMMENT This file is created by Vector NTI
http://www.biofeng.com/
COMMENT ORIGDB|GenBank|
COMMENT VNTAUTHORNAME|biofeng.com|
COMMENT VNTOAUTHORAD1|Novagen Inc.|
FEATURES Location/Qualifiers
source 1..3592
/organism="pET-23(+)"
/mol_type="other DNA"
terminator complement(1..129)
/label="T7_terminator"
misc_feature 69..87
/label="T7_Terminal_primer"
promoter complement(227..245)
/label="T7_promoter"
misc_feature 754..945
/label="ROP"
misc_feature complement(939..961)
/label="pGEX_3_primer"
rep_origin complement(1360..1979)
/label="pBR322_origin"
gene complement(2134..2994)
/label="Ampicillin"
/gene="Ampicillin"
CDS complement(2134..2994)
/label="ORF frame 2"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
promoter complement(3036..3064)
/label="AmpR_promoter"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
ORIGIN
1 atccggatat agttcctcct ttcagcaaaa aacccctcaa gacccgttta gaggccccaa
61 ggggttatgc tagttattgc tcagcggtgg cagcagccaa ctcagcttcc tttcgggctt
121 tgttagcagc cggatctcag tggtggtggt ggtggtgctc gagtgcggcc gcaagcttgt
181 cgacggagct cgaattcgga tcctagaggg aaaccgttgt ggtctcccta tagtgagtcg
241 tattaatttc gcgggatcga gatctcgggc agcgttgggt cctggccacg ggtgcgcatg
301 atcgtgctcc tgtcgttgag gacccggcta ggctggcggg gttgccttac tggttagcag
361 aatgaatcac cgatacgcga gcgaacgtga agcgactgct gctgcaaaac gtctgcgacc
421 tgagcaacaa catgaatggt cttcggtttc cgtgtttcgt aaagtctgga aacgcggaag
481 tcagcgccct gcaccattat gttccggatc tgcatcgcag gatgctgctg gctaccctgt
541 ggaacaccta catctgtatt aacgaagcgc tggcattgac cctgagtgat ttttctctgg
601 tcccgccgca tccataccgc cagttgttta ccctcacaac gttccagtaa ccgggcatgt
661 tcatcatcag taacccgtat cgtgagcatc ctctctcgtt tcatcggtat cattaccccc
721 atgaacagaa atccccctta cacggaggca tcagtgacca aacaggaaaa aaccgccctt
781 aacatggccc gctttatcag aagccagaca ttaacgcttc tggagaaact caacgagctg
841 gacgcggatg aacaggcaga catctgtgaa tcgcttcacg accacgctga tgagctttac
901 cgcagctgcc tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg
961 gagacggtca cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg
1021 tcagcgggtg ttggcgggtg tcggggcgca gccatgaccc agtcacgtag cgatagcgga
1081 gtgtatactg gcttaactat gcggcatcag agcagattgt actgagagtg caccatatat
1141 gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac cgcatcaggc gctcttccgc
1201 ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg tatcagctca
1261 ctcaaaggcg gtaatacggt tatccacaga atcaggggat aacgcaggaa agaacatgtg
1321 agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca
1381 taggctccgc ccccctgacg agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa
1441 cccgacagga ctataaagat accaggcgtt tccccctgga agctccctcg tgcgctctcc
1501 tgttccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg gaagcgtggc
1561 gctttctcat agctcacgct gtaggtatct cagttcggtg taggtcgttc gctccaagct
1621 gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg
1681 tcttgagtcc aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag
1741 gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt ggcctaacta
1801 cggctacact agaaggacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg
1861 aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggtttttt
1921 tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct caagaagatc ctttgatctt
1981 ttctacgggg tctgacgctc agtggaacga aaactcacgt taagggattt tggtcatgag
2041 attatcaaaa aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat
2101 ctaaagtata tatgagtaaa cttggtctga cagttaccaa tgcttaatca gtgaggcacc
2161 tatctcagcg atctgtctat ttcgttcatc catagttgcc tgactccccg tcgtgtagat
2221 aactacgata cgggagggct taccatctgg ccccagtgct gcaatgatac cgcgagaccc
2281 acgctcaccg gctccagatt tatcagcaat aaaccagcca gccggaaggg ccgagcgcag
2341 aagtggtcct gcaactttat ccgcctccat ccagtctatt aattgttgcc gggaagctag
2401 agtaagtagt tcgccagtta atagtttgcg caacgttgtt gccattgctg caggcatcgt
2461 ggtgtcacgc tcgtcgtttg gtatggcttc attcagctcc ggttcccaac gatcaaggcg
2521 agttacatga tcccccatgt tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt
2581 tgtcagaagt aagttggccg cagtgttatc actcatggtt atggcagcac tgcataattc
2641 tcttactgtc atgccatccg taagatgctt ttctgtgact ggtgagtact caaccaagtc
2701 attctgagaa tagtgtatgc ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa
2761 taccgcgcca catagcagaa ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg
2821 aaaactctca aggatcttac cgctgttgag atccagttcg atgtaaccca ctcgtgcacc
2881 caactgatct tcagcatctt ttactttcac cagcgtttct gggtgagcaa aaacaggaag
2941 gcaaaatgcc gcaaaaaagg gaataagggc gacacggaaa tgttgaatac tcatactctt
3001 cctttttcaa tattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt
3061 tgaatgtatt tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc
3121 acctgaaatt gtaaacgtta atattttgtt aaaattcgcg ttaaattttt gttaaatcag
3181 ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac
3241 cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaacgtgga
3301 ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggcccactac gtgaaccatc
3361 accctaatca agttttttgg ggtcgaggtg ccgtaaagca ctaaatcgga accctaaagg
3421 gagcccccga tttagagctt gacggggaaa gccggcgaac gtggcgagaa aggaagggaa
3481 gaaagcgaaa ggagcgggcg ctagggcgct ggcaagtgta gcggtcacgc tgcgcgtaac
3541 caccacaccc gccgcgctta atgcgccgct acagggcgcg tcccattcgc ca
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
, either alone or in combination with chemo- or radiotherapy at the more advanced stages. However, many patients present with metastatic disease at the time of diagnosis. Both computed tomography (CT) and positron emission tomography (PET) using fluorodeoxyglucose (FDG) play
什么是PET 树脂 ---PET是英文Polyethylene terephthalate的缩写，PET的中文意思是聚对苯二甲酸乙二醇酯。PET是以石油中的对苯二甲酸和乙二醇为原料，在高温高真空条件下进行化学反应而形成的树脂之一。PET瓶具有综合性能优良的特点，在饮料行业被广泛使用。 核医学 ---PET是英文Positron Emission Tomography的缩写，PET的中文意思是正电子发射计算机断层扫描。PET是核医学发展的一项新技术。 PET瓶片－－
PET and PET/CT in the Management of Thyroid Cancer
The introduction of PET(-CT) has brought about a major paradigm shift in the management of thyroid carcinoma, especially from the diagnostic standpoint. From the viewpoint of patient management, the areas where it has made significant impact
技术资料暂无技术资料 索取技术资料
pET-23(+)
¥1100
